DDInter1432 DDInter1676
An antipsychotic phenothiazine derivative with actions and uses similar to those of chlorpromazine.
Siponimod, also known as _Mayzent_, by Novartis, is a new drug formulated for the management of Multiple Sclerosis (MS). It was approved by the FDA on March 26, 2019 and by Health Canada on February 20, 2020. This drug is considered a _sphingosine-1-phosphate (S1P) receptor modulator_ and is thought to play a role in suppressing the central nervous system inflammation that is associated with MS [FDA label]. Multiple Sclerosis (MS) is an autoimmune disease of the central nervous system that is chronic and inflammatory, disrupting communication between the brain and other parts of the body. Most patients diagnosed with this illness experience their initial disease symptoms between the age of 20 to 40, often the most productive years of life. Symptoms may include but are not limited to fatigue, gait changes, bowel or bladder dysfunction, abnormal muscle twitching, vision disturbance, and depressing or mood swings. MS is one of the most common causes of neurological disability in young adults and is found to occur more frequently in women than in men.[A176474,L5792]
Perphenazine {u} (Compound) resembles {v} (Compound) Triflupromazine
Perphenazine {u} (Compound) resembles {v} (Compound) Propericiazine
Perphenazine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Cetirizine
Perphenazine {u} (Compound) binds {v} (Gene) CYP2C18
Perphenazine {u} (Compound) upregulates {v} (Gene) ST3GAL5
Perphenazine {u} (Compound) palliates {v} (Disease) Gilles de la Tourette syndrome
Perphenazine {u} (Compound) is included by {v} (Pharmacologic Class) Phenothiazines
Perphenazine {u} (Compound) downregulates {v} (Gene) TXNDC9
Perphenazine {u} (Compound) causes {v} (Side Effect) Nocturnal confusion
Perphenazine {u} may cause a minor interaction that can limit clinical effects when taken with {v} Sucralfate
Perphenazine (Compound) resembles Triflupromazine (Compound)
Perphenazine (Compound) resembles Propericiazine (Compound)
Perphenazine may cause a moderate interaction that could exacerbate diseases when taken with Cetirizine
Perphenazine (Compound) binds CYP2C18 (Gene)
Perphenazine (Compound) upregulates ST3GAL5 (Gene)
Perphenazine (Compound) palliates Gilles de la Tourette syndrome (Disease)
Perphenazine (Compound) is included by Phenothiazines (Pharmacologic Class)
Perphenazine (Compound) downregulates TXNDC9 (Gene)
Perphenazine (Compound) causes Nocturnal confusion (Side Effect)
Perphenazine may cause a minor interaction that can limit clinical effects when taken with Sucralfate